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Abstract
Background: Thrombus formation, a phenomenon primarily related to increased platelet activation, plays a key role
in cardiovascular and cerebrovascular diseases. Although the established antiplatelet agents, such as aspirin and
clopidogrel, have been shown to be beneficial in treating thromboembolic diseases, they have considerable
limitations. Hence, the development of more effective and safe antithrombotic agents is necessary to satisfy a
substantial unmet clinical need. In recent years, the favorable properties of imidazole-related drugs have prompted
medicinal chemists to synthesize numerous novel therapeutic agents. The chemical structure of the benzimidazole
backbone has proven antiplatelet properties. Moreover, synthetic oligosaccharides have exhibited antiplatelet
properties. Therefore, we developed a new aldo-benzimidazole-derived oligosaccharide compound, M3BIM, for
achieving a stronger antiplatelet effect than the drugs which are being used in clinical aspects. We investigated
the effects of M3BIM on platelet activation ex vivo and its antithrombotic activity in vivo.
Results: M3BIM (10–50 μM) exhibited a more potent activity in inhibiting platelet aggregation stimulated by
collagen than it did in inhibiting that stimulated by thrombin in washed human platelets. The M3BIM treatment
revealed no cytotoxicity in zebrafish embryos, even at the highest concentration of 100 μM. In addition, M3BIM
inhibited the phosphorylation of phospholipase Cγ2, protein kinase C (PKC), and mitogen-activated protein kinases
(MAPKs; extracellular signal-regulated kinase 2 and c-Jun N-terminal kinase 1), and markedly reduced the ATP-
release reaction and intracellular calcium mobilization in collagen-activated platelets. By contrast, M3BIM showed no
effects on either collagen-induced p38 MAPK and Akt phosphorylation or phorbol 12, 13-dibutyrate-induced PKC
activation and platelet aggregation. Moreover, the M3BIM treatment substantially prolonged the closure time in
human whole blood, and increased the occlusion time in mesenteric microvessels and attenuated cerebral
infarction in mice. For the study of anticoagulant activities, M3BIM showed no significant effects in the prolongation
of activated partial thromboplastin time and prothrombin time in mice.
Conclusion: The findings of our study suggest that M3BIM is a potential therapeutic agent for preventing or
treating thromboembolic disorders.
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Background
Thrombus formation plays a key role in the pathogenesis
of ischemic changes in various organs and systems of the
body such as arterial thrombosis and cerebrovascular dis-
eases. This phenomenon is primarily related to increased
platelet activity and intravascular thrombus formation [1].
The involvement of platelets in hemostasis is associated
with their ability to adhere and aggregate; release of the
storage granule content; adsorption, deposition, and trans-
portation of biologically active substances; and endothelial
supporting functions [2]. When the vascular endothelium
is disrupted, platelets adhere to the damaged intima and
undergo activation. During activation, platelets release
several mediators [including ADP and thromboxane A2
(TxA2)], which draw additional platelets toward the in-
jured endothelium, causing the initial platelet monolayer
to thicken. TxA2 is a crucial secondary mediator that is
produced and released by stimulated platelets. The con-
version of arachidonic acid (AA) into TxA2 is mediated by
cyclooxygenase-1 and can be irreversibly inhibited by as-
pirin, which remains the standard drug for preventing car-
diovascular diseases [3]. The use of antiplatelet drugs for
various manifestations of activation of the platelet compo-
nent of hemostasis can reduce the risk of thrombotic com-
plications. Although the established antiplatelet agents,
such as aspirin, clopidogrel, and tirofiban, have been shown
to be beneficial in treating thromboembolic diseases, they
have considerable limitations [4, 5]. Therefore, there is a
great unmet clinical need for developing more effective
and safe antithrombotic agents. Because the recent litera-
ture has emphasized the vital role of TxA2 in several path-
ologies, drugs that target the TxA2 pathway in platelets
have emerged, including various TxA2 receptor antagonists
(S-18886) [6], TxA2 synthase inhibitors (furegrelate) [7],
and compounds combining both functions (ridogrel) [8].
However, the clinical efficacy of these inhibitors remains
unclear.
Benzimidazole derivatives belong to a group of mole-
cules that can be used to synthesize new substances with
various biological properties [9]. In recent years, the fa-
vorable therapeutic properties of imidazole-related drugs
have prompted medicinal chemists to synthesize numerous
novel therapeutic agents. Imidazole-containing compounds
have various medicinal properties such as anticancer [10],
antimicrobial [11], antibacterial [12], and antifungal prop-
erties [13]. Compounds with a chemical structure contain-
ing a benzimidazole backbone have been shown to
suppress platelet aggregation by inhibiting TxA2 synthase
activity [14, 15]. Moreover, during the past decades, clarifi-
cations of the mechanisms of heparin and progress in
oligosaccharide chemistry have facilitated the development
of synthetic oligosaccharides [16]. Synthetic oligosacchar-
ide polymers contain between three and ten simple sugars.
Synthetic oligosaccharides also exhibit antiplatelet proper-
ties [17]. Encouraged by these observations to discover
new biologically active benzimidazole-oligosaccharide
compounds, we developed a new aldo-benzimidazole-
derived oligosaccharide compound, M3BIM, from D-
maltotriose (Fig. 1) to achieve stronger antiplatelet effects.
This study provides the first evidence that the novel com-




Collagen (type I), luciferin-luciferase, arachidonic acid
(AA), U46619, PDBu, heparin, prostaglandin E1 (PGE1),
2,3,5-triphenyl tetrazolium chloride (TTC), and throm-
bin were purchased from Sigma (St. Louis, MO, USA).
Fura 2-AM, an intracellular calcium indicator, was pur-
chased from Molecular Probes (Eugene, OR, USA). The
anti-phospho-p38 MAPK Ser182 monoclonal antibody
(mAb) was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The anti-p38 MAPK, anti-
phospho-JNK (Thr183/Tyr185), and anti-p44/42 ERK
(1/2) mAbs and anti-PLCγ2, anti-phospho (Tyr759)
PLCγ2, the anti-phospho-(Ser) PKC substrate, anti-JNK




Fig. 1 Chemical structure of benzimidazole-derived oligosaccharide (M3BIM)
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polyclonal antibodies (pAbs) were purchased from Cell
Signaling (Beverly, MA, USA). The anti-phospho-Akt
(Ser473) and anti-Akt mAbs were purchased from Biovi-
sion (Mountain View, CA, USA). Anti-pleckstrin (p47)
pAb was purchased from GeneTex (Irvine, CA, USA).
The anti-α-tubulin mAb was purchased from NeoMarkers
(Fremont, CA, USA). A hybond-P PVDF membrane, an
enhanced chemiluminescence Western blotting detection
reagent, the horseradish peroxidase (HRP)-conjugated
donkey anti-rabbit immunoglobulin G (IgG), and the
sheep anti-mouse IgG were purchased from Amersham
(Buckinghamshire, UK). The Dade Behring PFA-100 CEPI
and CADP test cartridges were obtained from Siemens
Healthcare (Erlangen, Germany).
Preparation and purification of M3BIM from maltotriose
According to the method described by Lin et al. [18], the
compound M3BIM was prepared and purified through
the oxidative condensation of maltotriose. Briefly, a mix-
ture of D-maltotriose monohydrate (50.4 mg, 0.1 mM)
and o-phenylenediamine (21.6 mg, 0.2 mM) was stirred
with iodine (25 mg, 0.1 mM) in 3.0 mL of acetic acid for
30 h. The reaction was completed in 6 h as indicated by a
subsequent thin layer chromatography analysis: (acetone/
ethyl acetate/water/acetic acid, 60:30:20:1) Rf) 0.44; [R] 25
D + 55.40 (c 1.0, H2O). The reaction mixture was tritu-
rated with ethyl acetate to obtain precipitates, which were
collected through filtration using a nylon membrane filter.
The aldo-naphthimidazole products prepared using the
aforementioned processes were essentially pure for
characterization. The crude product was purified through
C18 reversed-phase silica gel column chromatography
(methanol/water, 1 to 30 % as gradient) to yield the prod-
uct M3BIM (30 mg, 51 % yield, C24H36N2O15, yellowish
foam). The freshly obtained M3BIM was dissolved in
DMSO and stored at 4 °C.
Platelet aggregation
This study was approved by the Institutional Review
Board of Taipei Medical University and conformed to
the directives of the Helsinki Declaration. All human
volunteers who involved this study provided informed
consent. Human platelet suspensions were prepared as
previously described [19]. The human blood samples
were obtained from adult volunteers, who refrained from
the use of drugs or other substances that could interfere
with the experiment for at least 14 days prior and mixed
with an acid-citrate-dextrose solution. After centrifuga-
tion, the platelet-rich plasma was supplemented with
0.5 μM PGE1 and 6.4 IU/mL of heparin. A Tyrode’s so-
lution containing 3.5 mg/mL of bovine serum albumin
(BSA) was used to make final suspension of washed hu-
man platelets. The final concentration of Ca2+ in Tyrode’s
solution was 1 mM. The platelet aggregation test was
performed by using lumiaggregometer (Payton Associates,
Scarborough, ON, Canada) as previously described [19].
Various concentrations of M3BIM or the solvent control
(0.5 % DMSO) were preincubated into platelet suspen-
sions (3.6 × 108 cells/mL) for 3 min before adding agonists
(i.e., collagen). The extent of platelet aggregation was cal-
culated as a percentage of the control (absence of
M3BIM) of light-transmission units, after the reaction was
preceded for 6 min. For tests of ATP release assay, 20 μL
of a luciferin-luciferase mixture was added 1 min before
the addition of the agonist, and the amount of ATP release
was compared with that released by the control.
Measurement of intracellular [Ca2+]i mobilization using
Fura 2-AM fluorescence
The amount of intracellular calcium concentration
[Ca2+]i was determined with Fura 2-AM as described
previously [19]. Briefly, citrated whole blood was cen-
trifuged at 120 × g for 10 min, and the collected
supernatant was incubated with 5 μM Fura 2-AM for
1 h. Human platelets were prepared as described in
the previous section. The Fura 2-loaded platelets were
washed and pre-incubated with M3BIM in the pres-
ence of 1 mM CaCl2, and subsequently stimulated
with collagen. The Fura 2 fluorescence was measured
in a spectrofluorometer (Hitachi FL Spectrophotom-
eter F-4500, Tokyo, Japan) with excitation wavelengths
of 340 nm and 380 nm, and with the emission wave-
length of 510 nm.
Zebrafish toxicity test
Zebrafish (Danio rerio) were obtained from the zebrafish
core facility of Taipei Medical University and maintained
at 28 °C on a 14 h light/10 h dark cycle. All animal pro-
cedures were approved by the Taipei Medical University
Institutional Animal Care and Utilization Committee.
The zebrafish embryos were incubated at 28 °C and the
developmental stages were determined using The Zebra-
fish Book [20]. Wild-type embryos were treated with
various concentrations of M3BIM at 20 h postfertiliza-
tion for 144 h to evaluate the toxic effects of M3BIM on
the zebrafish embryos. Fifteen dechorionated embryos
were treated with 2 mL of M3BIM (10, 20, 50, or
100 μM) or a solvent control (0.5 % DMSO) in a 24-well
chamber. The treated embryos were observed at 2, 3, 4,
5, or 6 dpf. At 6 dpf, the percentage of embryos exhibit-
ing developmental abnormalities and the survival rate
were determined. During the exposure period, photo-
graphs of the embryos were observed under an Olympus
IX70-FLA inverted fluorescence microscope (Olympus,
Tokyo, Japan). The images were taken using a SPOT
digital camera system (Diagnostic Instruments, Sterling
Heights, MI, USA) and assembled using the Image J pro-
gram [21].
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Immunoblotting
Washed platelets (1.2 × 109 cells/mL) were preincubated
with various concentrations of M3BIM or a solvent con-
trol (0.5 % DMSO) for 3 min, followed by the addition
of collagen to trigger platelet activation. The reaction
was stopped, and the platelets were immediately resus-
pended in 200 μL of a lysis buffer. Samples containing
80 μg of protein were separated through 12 % SDS gel
electrophoresis, and the proteins were electrotransferred
to the PVDF membranes by using a Bio-Rad semidry
transfer unit (Hercules, CA, USA). The blots were
blocked with Tris-buffered saline in Tween 20 (TBST;
10 mM Tris-base, 100 mM NaCl, and 0.01 % Tween 20)
containing 5 % BSA for 1 h and probed with various pri-
mary antibodies. The membranes were incubated with
HRP-linked anti-mouse IgG or anti-rabbit IgG (diluted
1:3000 in TBST) for 1 h. An enhanced chemilumines-
cence system was used to detect immunoreactive bands,
and their optical density was quantified by using Bio-profil
Biolight software, Version V2000.01 (Vilber Lourmat,
Marne-la-Vallée, France).
Platelet function analysis in whole blood
The Dade Behring PFA-100 System (Marburg, Germany)
was used to analyze platelet function [22]. Cartridges
containing CADP- and CEPI-coated membranes were
preincubated with various concentrations of M3BIM or
the solvent control (0.5 % DMSO) for 2 min. Whole
blood aliquots (0.8 mL/cartridge) were applied to the
cartridges before the contents were exposed to high
shear flow conditions (5000 to 6000/s). The CT was de-
fined as the time required for a platelet plug to occlude
the aperture in the collagen membrane [22].
Measurement of sodium fluorescein-induced platelet
thrombus formation in mice mesenteric microvessels
Male ICR mice (6 weeks) were anesthetized using a mix-
ture containing 75 % air and 3 % isoflurane maintained
in 25 % oxygen, and the external jugular vein was can-
nulated with a PE-10 tube for administering the dye and
drugs intravenously [23]. Venules (30–40 μm) were irra-
diated at wavelengths < 520 nm to produce a micro-
thrombus. Two doses of M3BIM (12 and 24 mg/kg)
were administered 1 min following sodium fluorescein
(15 μg/kg) administration and the time required for the
thrombus to occlude the microvessel (occlusion time)
was recorded. In this experiment, the method of
thrombogenic animal model was conformed to the
Guide for the Care and Use of Laboratory Animals (NIH
publication no. 85–23, 1996).
MCAO-induced focal cerebral ischemia in mice
Male C57/BL6 (6 weeks) mice were used in this study.
All mice were clinically normal and free of apparent
infections or inflammation, and showed no neurological
deficits. The animals were anesthetized with a mixture
of 95 % O2 and 5 % CO2 gasses containing 3 % isoflur-
ane. The rectal temperature was maintained at 37 ± 0.5 °C.
The right middle cerebral artery (MCA) was occluded as
described by Hsiao et al. [23]. Briefly, the right common
carotid artery was exposed and a 6–0 monofilament nylon
thread coated with silicon was then inserted from the exter-
nal carotid artery into the internal carotid artery until the
tip occluded the origin of the MCA. After the closure of
the operative sites, the animals were allowed to awaken
from the anesthesia. During another brief period of
anesthesia, the filament was gently removed after 30 min of
MCAO. An observer blinded to the identity of the groups
assessed neurological deficits at 1 and 24 h after reperfusion
(before sacrifice) by using the forelimb akinesia (also called
postural tail-hang) test, and the spontaneous rotational test
was used for evaluating the ischemic insult [24]. Animals
not showing behavioral deficits at the aforementioned time
points after reperfusion were excluded from the study.
The mice were sacrificed through decapitation after
24 h of reperfusion. The brains were cut into 2-mm-
thick coronal slices. Each stained (2 % TTC) brain slice
was drawn using a computerized image analyzer (Image-
Pro Plus). The calculated infarction areas were then
compiled to obtain the infarct volumes (mm3) per brain.
Infarct volumes were expressed as a percentage of the
contralateral hemisphere volume by using the following
formula to compensate for edema formation in the ipsi-
lateral hemisphere: [area of the intact contralateral (left)
hemisphere] − [area of the intact region of the ipsilateral
(right) hemisphere] [23]. All animals were allocated into
four groups: a sham-operated group, a solvent control
(DMSO) group, and groups treated with 12 or 24 mg/kg
(i.p.) of M3BIM.
Ex vivo coagulation time assays
M3BIM (24 mg/kg), solvent control (0.5 % DMSO), or a
phosphate-buffered saline (PBS) was injected (i.p.) in male
ICR mice (6 weeks) for 30 or 60 min. The animals were
then anesthetized using a mixture containing 75 % air and
3 % isoflurane maintained in 25 % oxygen. Whole blood
(0.45 mL) was collected by cardiac puncture and trans-
ferred into plastic tubes containing 0.05 mL of 3.2 %
citrate and was gently mixed. Specimens were centrifuged
to obtain platelet-poor plasma. Activated partial thrombo-
plastin time (APTT) and prothrombin time (PT) were
obtained on a coagulation analyzer (Diagnostica Stago,
Asnieres, France) using standard reagents according to
the manufacturer’s instructions.
Statistical analysis
The experimental results are expressed as the means ±
SEM and are accompanied by the number of observations
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(n). Values of n refer to the number of experiments, and
each experiment was conducted using different blood do-
nors. Paired and unpaired Student’s t tests were used to
determine significant differences in the occlusion time
and MCAO-induced cerebral ischemia in mice, respect-
ively. The differences between the groups in other ex-
periments were assessed using ANOVA. When the
ANOVA indicated significant differences among the
group means, the groups were then compared using the
Student-Newman-Keuls method. A value of P < 0.05 in-
dicated statistical significance. Statistical analyses were
performed using SAS Version 9.2 (SAS Inc., Cary, NC,
USA).
Results
Inhibitory effects of M3BIM on platelet aggregation in
washed human platelets
As shown in Fig. 2a-b, M3BIM (10, 25, and 50 μM)
concentration-dependently inhibited platelet aggregation
in washed human platelets stimulated by 1 μg/mL of
collagen. M3BIM exhibited similar inhibitory activity at
a high concentration (100 μM) stimulated by 0.01 U/mL
of thrombin (Fig. 2b). Moreover, M3BIM exhibited a
slight inhibitory activity of platelet aggregation at very
high concentration (500 μM) stimulated by 120 μM of
AA (Fig. 2c) or 0.5 μΜ of U46619, a prostaglandin endo-
peroxide (Fig. 2d), indicating that M3BIM had no signifi-
cant effects on thromboxane A2/prostaglandin E1 (TP)
receptors or TP-synthesizing enzymes. The 50 % inhibi-
tory concentration (IC50) values of M3BIM for platelet
aggregation induced by collagen and thrombin were ap-
proximately 25 μM and 70 μM (Fig. 2e), respectively.
M3BIM showed more potent activity in inhibiting
collagen-stimulated platelet aggregation than it did in
inhibiting thrombin-stimulated platelet aggregation. The
solvent control (0.5 % DMSO) did not significantly affect
platelet aggregation (Fig. 2a-b). In subsequent experi-
ments, 1 μg/mL of collagen was used as an agonist for
platelet activation.
Influence of M3BIM toxicity in zebrafish embryos and
ATP-release reaction and intracellular [Ca2+]i mobilization
in washed human platelets
To assess the M3BIM toxicity potential at the organism
level, zebrafish, a versatile in vivo vertebrate model used
in many areas of biological investigation, were used for
this study. We evaluated the toxicity of M3BIM at
ranges of 10–100 μM in wild-type zebrafish embryos
treated for 6 days postfertilization (dpf ). The results ob-
tained from this assay showed no significant phenotypic
differences between solvent control (0.5 % DMSO)- and
M3BIM-treated zebrafish embryos throughout the ex-
periment (n = 15) (Fig. 3aa-b). Notably, no developmen-
tal defects or decreases in viability (Fig. 3aa) were
observed in the zebrafish embryos in the presence of
M3BIM, event at the highest concentration of 100 μM.
Furthermore, the aggregation curves of platelets that
were preincubated with 100 μM M3BIM for 10 min
and subsequently washed twice with Tyrode’s solution
showed no significant differences from those of plate-
lets preincubated with the solvent control (0.5 %
DMSO) under equivalent conditions (data not shown).
These results indicate that the inhibitory effects of
M3BIM on platelet aggregation are reversible and
noncytotoxic.
Platelet activation by several agonists is associated with
the release of granular contents (e.g., release of ADP/ATP,
calcium, and serotonin from dense granules) resulting in
ample platelet aggregation. In the present study, we ob-
served that M3BIM (25 and 50 μM) concentration-
dependently inhibited both the ATP-release reaction
(Fig. 3b) and relative [Ca2+]i mobilization (Fig. 3c) in
washed human platelets stimulated by 1 μg/mL of collagen.
As shown in Fig. 3c, collagen induced a relative increase in
[Ca2+]i that was concentration-dependently inhibited by
25 and 50 μM M3BIM (resting, 19.0 ± 2.7 nM; collagen-
activated, 132.7 ± 12.5 nM; 25 μM, 47.1 ± 22.8 nM; 50 μM,
25.5 ± 11.2 nM).
M3BIM’s regulatory activity on phospholipase Cγ2 and
protein kinase C activation
The phospholipase C (PLC) enzyme hydrolyzes phos-
phatidylinositol 4,5-bisphosphate to generate the sec-
ondary messengers inositol 1,4,5-trisphosphate (IP3) and
diacylglycerol (DAG). IP3 triggers intracellular Ca2 + i
mobilization and DAG activates protein kinase C (PKC)-
inducing protein phosphorylation (p47 protein; pleck-
strin) and the ATP-release reaction in activated platelets
[25]. We thus investigated the influence of M3BIM on
phosphorylation of the PLCγ2-PKC signaling cascade.
M3BIM treatment at concentrations of 25 and 50 μM
evidently reduced PLCγ2 phosphorylation in collagen-
activated platelets (Fig. 4a). Platelet stimulation by vari-
ous agonists induces PKC activation and the subsequent
phosphorylation of p47 proteins. A protein with an ap-
parent molecular weight similar to that of p47 (47 kDa)
was predominantly phosphorylated in collagen- and (150
nM) phorbol 12, 13-dibutyrate (PDBu, a PKC activator)-
activated human platelets (Fig. 4b-c) compared with the
proteins in non-activated platelets. M3BIM treatment at
25 and 50 μM reduced the evident collagen-induced p47
phosphorylation (Fig. 4b), but not PDBu-induced p47
phosphorylation, even concentration up to 100 or 200 μM
(Fig. 4c). In addition, neither 50 nor 100 μM M3BIM sig-
nificantly affected PDBu-induced platelet aggregation
(Fig. 4d), indicating that M3BIM inhibits PKC activation
through the upstream regulator PLCγ2.
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Inhibitory effect of M3BIM on Akt and mitogen-activated
protein kinase activation
To investigate the inhibitory mechanisms of M3BIM in
platelet activation, we detected several signaling mole-
cules, such as Akt and mitogen-activated protein kinases
(MAPKs). Akt is a Ser-Thr kinase with pleiotropic ef-
fects on cell survival, growth, and metabolism. MAPKs,
including extracellular signal-regulated kinases 1 and 2
(ERK1/2), c-Jun N-terminal kinases 1 and 2 (JNK1/2),
and p38 MAPK, control major cellular responses in
eukaryotic organisms and contribute to cell proliferation,
migration, differentiation, and apoptosis. M3BIM (25
and 50 μM) had no effects on inhibition of Akt or p38
MAPK phosphorylation (Fig. 5a-b); however, M3BIM
(25 and 50 μM) concentration-dependently inhibited
both ERK2 and JNK1 phosphorylation (Fig. 5c-d),
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Fig. 2 Inhibitory effects of M3BIM on agonist-induced platelet aggregation in washed human platelets. Washed human platelets (3.6 × 108 cells/mL)
were preincubated with M3BIM (10–500 μM) or a solvent control (0.5 % DMSO) and subsequently treated with 1 μg/mL of collagen a, 0.05 IU/mL of
thrombin b, 120 μM arachidonic acid c, or 0.5 μM U46619 d to stimulate platelet aggregation. The concentration-response curves of
M3BIM in inhibiting platelet aggregation stimulated by collagen (○), thrombin (□), arachidonic acid (△) and U46619 (▽) are shown in e,
and data are presented as the means ± SEM (n = 4)
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indicating that the inhibition of the ERK2 and JNK1 sig-
naling pathway is a crucial process in M3BIM-mediated
inhibition of platelet activation.
Ex vivo and in vivo studies of the role of M3BIM in
thrombus formation and cerebral infarction
In the present study, shear-induced platelet plug forma-
tion in whole blood was tested ex vivo. The PFA-100 in-
strument was used to mimic the in vivo conditions of
blood vessel injury, in which platelets were exposed to a
high shear rate to record the time required for platelet
aggregation to occlude an aperture in a collagen-coated
membrane. The closure times (CTs) of collagen/ADP
(CADP) and collagen/epinephrine (CEPI) membranes in
whole blood treated with a solvent control (0.5 %
DMSO) were 80.0 ± 2.7 and 89.8 ± 2.9 s (n = 6), respect-
ively (Fig. 6aa-b). Treatment with 50 μM M3BIM signifi-
cantly increased the CTs of CADP (25 μM, 84.2 ± 1.3 s;
50 μM, 93.2 ± 2.9 s, n = 6) and CEPI (25 μM, 96.6 ± 4.2 s;
50 μM, 108.6 ± 2.0 s, n = 6) (Fig. 6aa-b), indicating that
platelets were unable to adhere to collagen under flow
conditions after the 50 μM M3BIM treatment. Further-
more, we investigated the effect of M3BIM on thrombus
formation in vivo. The occlusion time in microvessels
pretreated with 15 μg/kg of fluorescein sodium was ap-
proximately 180 s. When M3BIM was administered at
12 or 24 mg/kg after pretreatment with fluorescein so-
dium, the occlusion times were significantly prolonged
at dose of 24 mg/kg compared with those of the solvent
control groups (0.5 % DMSO, 172.5 ± 6.0 s vs 12 mg/kg,
180.6 ± 9.6 s, n = 8, P > 0.05; 0.5 % DMSO, 188.2 ± 7.2 s
vs 24 mg/kg, 309.1 ± 15.3 s, n = 8, P < 0.001) (Fig. 6ba).
After irradiation, a thrombotic platelet plug was ob-
served in mesenteric microvessels at 350 s, but not at
5 s in the control group (Fig. 6bb). Upon the administra-
tion of 24 mg/kg of M3BIM, platelet plug formation was
not observed at 5 or 350 s after irradiation (Fig. 6bb).































































Fig. 3 Influence of M3BIM on zebrafish embryonic development, and the ATP-release reaction and relative [Ca2+]i mobilization in human platelets.
Wild-type zebrafish embryos (arrows) at 6 day postfertilization exposed to various concentrations of M3BIM (10, 20, 50, and 100 μM) or
a solvent control (0.5 % DMSO) (scale bar 100 μm) (a,a). Statistical graphs (a,b) show the means ± SEM (n = 15). For other experiments,
washed platelets (3.6 × 108 cells/mL) were preincubated with M3BIM (10, 20, 50, and 100 μM) or the solvent control (0.5 % DMSO), and
1 μg/mL of collagen was then added to stimulate either the ATP-release reaction (b) or to induce relative [Ca2+]i mobilization (c). Profiles
(b and c) are representative of four independent experiments
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that in the M3BIM-treated venule, because a platelet
plug appeared at 350 s in the control venule (Fig. 6bb).
Platelet activation is relevant to various cerebrovascu-
lar disorders (e.g., ischemic stroke). Antiplatelet agents
(e.g., acetylsalicylic acid and ticlopidine) have been
shown to reduce the incidence of ischemic stroke in
high-risk patients [26]. Therefore, we investigated the
potential cerebroprotective effect of M3BIM after middle
cerebral artery occlusion (MCAO) reperfusion in mice.
All mice showed similar physiological values for rectal
temperature, mean arterial blood pressure, plasma glu-
cose, and hematocrit (%) before, during, and after
MCAO (data not shown). Figure 6ca shows coronal sec-
tions of an ischemic brain (white area) from the sham
control group and solvent control (0.5 % DMSO)-treated
group, and coronal sections of the brain from mice pre-
treated with 12 and 24 mg/kg of M3BIM before ische-
mic insult. M3BIM treatment at the dose of 24 mg/kg
(infarct volume, 22.7 ± 3.9 %, n = 8) but not at 12 mg/kg
(infarct volume, 40.8 ± 5.3 %, n = 8), showed significant
reductions in the infarct size compared with that in the
mice treated with the solvent control (50.1 ± 3.0 %, n = 8)
(Fig. 6cb).
The influence of coagulation parameters in vitro by
M3BIM
To further investigate whether the M3BIM also pos-
sesses anticoagulant activity, the APTT and PT was de-
termined using mice blood, indicators for the efficacy of
intrinsic and extrinsic pathways, respectively. As shown
in the Table 1, M3BIM (24 mg/kg) had no significant
prolongation of the APTT and PT values after 30 or
60 min treatment as compared with the PBS or solvent
control (0.5 % DMSO), respectively. Positive control
(warfarin, 3 mg/kg) markedly prolonged the APTT and
PT values after 30 min treatment as compared with the
PBS (APTT, warfarin, 80.6 ± 9.6 s vs PBS, 40.4 ± 2.7 s, n = 5,
P < 0.01; PT, warfarin, 20.6 ± 2.9 s vs PBS, 13.1 ± 0.4 s,
n = 5, P < 0.05; data not shown).
Time (s)






























































Fig. 4 Regulatory effects of M3BIM on PLCγ2 and PKC activation in platelets. Washed platelets were preincubated with 25 or 50 μM M3BIM or a
solvent control (0.5 % DMSO) and subsequently treated with 1 μg/mL of collagen or 150 nM PDBu to induce either PLCγ2 a or PKC activation
(p47 phosphorylation) b and c and platelet aggregation d. Data are presented as the means ± SEM (n = 4). ** P < 0.01 and *** P < 0.001,
compared with the resting platelets; # P < 0.05 and ## P < 0.01, compared with the platelets receiving the solvent control. Profiles d are
representative of four independent experiments
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Discussion
Our results show that M3BIM, a novel synthetic
benzimidazole-derived maltotriose, exhibits potent anti-
platelet activity ex vivo and effectively inhibits arterial
thrombogenesis in vivo. Platelets are activated by a var-
iety of physiological stimuli (e.g., thrombin and colla-
gen). These agonists are thought to exert their effects by
interacting with specific receptors on the platelet mem-
branes. Thrombin is one of the most potent activators of
platelets and its role in promoting thrombus formation
has been clearly established. Thrombin activates platelets
through multiple cell-surface receptors, including the
glycoprotein (GP) Ib/V/IX complex and the protease-
activated receptors (PARs) [27]. Of the 4 known PAR
isoforms, PAR1, PAR3, and PAR4 constitute the active
thrombin receptors on human platelets [28]. PAR1 and
PAR4 are essential for thrombin-induced human platelet
activation [29]. In addition, platelets adhere to the con-
nective tissue protein collagen, with a resulting change
in shape and the release of granules. The matrix protein
collagen is present in the vascular subendothelium and
vessel wall, and acts as a substrate for platelet adhesion;
it is also an endogenous platelet activator. Among the
platelet receptors known to interact directly with colla-
gen, integrin α2β1 (GP Ia/IIa) and GP VI might contrib-
ute to the overall processes of platelet adhesion and
activation [30–32]. In the present study, M3BIM inhib-
ited platelet aggregation stimulated by collagen and
thrombin, which indicates M3BIM was not effective on
the specific/individual receptors of these agonists; how-
ever it may act via a common signal cascade against
stimulated human platelets.
The activation of platelets by agonists, such as colla-
gen, substantially alters phospholipase activation. The
activation of PLC results in IP3 and DAG production,
which activates PKC, inducing the phosphorylation of
the p47 protein [25]. PKC activation enables particular
responses that facilitate the transmission of specific acti-
vating signals in distinct cellular compartments. PLC




































































Fig. 5 Effects of M3BIM on Akt, p38 MAPK, ERK2, and JNK1 phosphorylation in collagen-activated platelets. Washed platelets (1.2 × 109 cells/mL)
were preincubated with 25 or 50 μM M3BIM or a solvent control (0.5 % DMSO) and subsequently treated with 1 μg/mL of collagen to induce
platelet activation. The platelets were collected and the subcellular extracts were analyzed to determine the levels of Akt a, p38 MAPK b, ERK2 c,
and JNK1 phosphorylation d. Data are presented as the means ± SEM (n = 4). *** P < 0.001, compared with the resting platelets; # P < 0.05 and ##
P < 0.01, compared with the platelets receiving the solvent control
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PLCδ, PLCε, PLCζ, and PLCη [33]. The PLCγ family
comprises isozymes 1 and 2. PLCγ2 is involved in
collagen-dependent signaling in platelets [34]. In our
study, M3BIM diminished collagen-induced PLCγ2-PKC
activation; however, M3BIM exerted no direct effects on
PKC activation, because it did not reduce PDBu-induced
PKC activation or platelet aggregation, suggesting that
M3BIM-mediated inhibition of platelet activation involves
PLCγ2 downstream signaling. This result also explains
how M3BIM comparatively efficacious in collagen-
induced platelet aggregation than that of thrombin.
MAPKs are activated by specific MAPK kinases
(MAPKKs or MEKs); specifically, MEK1/2 activates
















































































Fig. 6 Protective effects of M3BIM on the closure time according to the PFA-100 analysis and thrombotic platelet plug formation in the mesen-
teric venules of mice, and middle cerebral artery occlusion (MCAO)-induced cerebral infarction in mice. (a) Shear-induced platelet plug formation
in whole blood was determined by recording the (a) closure time of collagen/ADP (CADP) and (b) closure time of collagen/epinephrine (CEPI) as
described in the Methods. (b) The mice were administered an intravenous bolus of a solvent control (0.5 % DMSO) or M3BIM (12 or 24 mg/kg),
and the mesenteric venules were irradiated to induce microthrombus formation (occlusion time, a). Microscopic images (×400 magnification) of
the solvent control- and M3BIM (24 mg/kg)-treated groups were recorded at 5 and 350 s after irradiation (b). The arrow indicates platelet plug
formation. (c) Digital photographs (a) and dose–response bars (b) show the infarct region in brain sections stained with 2 % TTC 24 h after MCAO.
Mice were injected with the solvent control or M3BIM (12 or 24 mg/kg, i.p.) before the onset of MCAO, and the infarct volume was compared
with that of the sham group, as described in the Methods. The infarct volumes are expressed as a percentage of the contralateral hemisphere.
Data (a-c) are presented as means ± SEM (A, n = 6; B-C, n = 8). * P < 0.05 and *** P < 0.001, compared with the DMSO group (a and b) or the sham
group (c); ###P < 0.001, compared with the DMSO group (c)
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activates JNK1/2 [35]. Extensive studies have clarified
that various growth factors and hormones that lead to
cellular proliferation can activate the ERK1/2 signaling
pathway via a Ras/Raf1/MEK1 signaling cascade [35]. In
addition, various inflammatory cytokines and stress
stimuli, which lead to cellular apoptosis or hypertrophy,
activate JNK1/2 and p38 MAPK [35, 36]. ERK2, JNK1,
and p38 MAPK were identified in platelets [37]. Little
information is available on the molecular basis of the
signaling pathway involved in ERK2 activation in plate-
lets; however, a study reported that ERK2 activation de-
pends on PKC and Src activation and increased myosine
light chain kinase phosphorylation [38]. In addition, p38
MAPK plays a crucial role in platelet activation. Among
the numerous downstream targets of p38 MAPK, cyto-
solic phospholipase A2, which catalyzes AA release to
produce TxA2, is the most physiologically relevant [39].
JNK1 is the most recently identified MAPK in platelets,
and its activation and role are therefore poorly defined.
JNK1 activation was reported to trigger integrin αIIbβ3
activation [38]. Thus, MAPKs, particularly ERK2 and
JNK1, but not p38 MAPK, appear to play a crucial role
in M3BIM-mediated inhibition of platelet activation.
Furthermore, Akt is a downstream effector of phosphoi-
nositide 3-kinase (PI3-kinase) [40], and Akt-knockout
mice have been shown to exhibit defects in agonist-
induced platelet activation [41, 42]. In the present study,
neither Akt nor p38 MAPK phosphorylation was inhib-
ited by M3BIM. These findings are consistent with those
of our previous study, where PI3-kinase/Akt and p38
MAPK were mutually activated in platelets [43].
After vascular endothelial cell injury, exposure to sub-
endothelial collagen is the major trigger that initiates
platelet adhesion and aggregation at the site of injury,
followed by arterial thrombus formation. The PFA-100
instrument records the time required for platelet aggre-
gation to occlude an aperture in a collagen-coated mem-
brane. Platelet adhesion to collagen depends on flow
conditions, and, in this study, platelets depleted of activity
was unable to adhere to collagen under flow conditions.
In a thrombosis study, the mesenteric venules were con-
tinuously irradiated by fluorescein sodium throughout the
experimental period, leading to strong damage to the
endothelial cells [19]. Cerebral ischemia restricted to the
area of MCAO engenders focal metabolic disturbances
that result in infarction, neuronal necrosis, and brain
edema [23, 44]. In this study, M3BIM significantly re-
duced both arterial thrombosis and cerebral infarction;
this effect may be mediated, at least partly, by inhibition of
platelet activation. Furthermore, in the current study, we
also examined the anticoagulant activity of M3BIM. There
are two distinct pathways described for initiating blood
coagulation, triggered by either vessel wall (extrinsic) or
blood-borne (intrinsic) factors, which converge on a com-
mon pathway leading to thrombin generation and fibrin
formation. Induction of fibrin clot formation through
contact activation-mediated activation of factor XII in the
intrinsic pathway is the basis of the APTT assay, a com-
monly used method for assessment of plasma coagulation
in clinical settings [15]. The PT is an assay for the activa-
tion of coagulation through the extrinsic pathway trig-
gered by factor VII coming into contact with tissue factor
[15]. In the present study, we found that M3BIM had no
effects on coagulant activities as it did not affect the
APTT and PT values. In addition, the tail transection
model of mice was used to examine the influence of
M3BIM on bleeding time in vivo. Aspirin is the most ef-
fective antiplatelet drug prescribed for the prevention or
treatment of cardiovascular and cerebrovascular diseases,
whereas it has unwanted prolongation of the bleeding
time. In the tail transection model of mice, aspirin was ad-
ministered (i.p.) at 150 mg/kg after 30 min markedly pro-
longed the bleeding from 217.8 ± 19.0 s (PBS-treated
control group; n = 8) to 428.1 ± 20.8 s (n = 8, P < 0.01; data
not shown). The bleeding time of the M3BIM (24 mg/kg)-
treated mice was slightly prolonged as compared with the
solvent control (0.5 % DMSO)-treated mice (226.2 ± 19.5 s
vs 288.6 ± 11.5 s, n = 8, P < 0.05; data not shown), indicat-
ing that the slightly prolonged the bleed time of M3BIM
may be resulted, at least partly, from its antiplatelet
activity.
Conclusion
The findings of the current study reveal that M3BIM plays
a novel role in inhibiting platelet activation. We report
that M3BIM inhibits platelet activation by inhibiting the
PLCγ2-PKC cascade and, subsequently, by suppressing
ERK2 and JNK1 activation. These alterations reduce the
level of [Ca2+]i and ATP-release reaction, and ultimately
inhibit platelet aggregation. However, our experiments did
not rule out the possibility that other as-yet-unidentified
mechanisms might be involved in M3BIM-mediated plate-
let activation. Our findings suggest that a new class of syn-
thetic benzimidazole-oligosaccharide derivative, M3BIM,
is a novel potential therapeutic agent for preventing or
treating thromboembolic disorders.
Table 1 The influence of M3BIM on activated partial
thromboplastin time and prothrombin time in mice
PBS 0.5 % DMSO M3BIM
30 min 30 min 30 min 60 min
APTT (s) 40.4 ± 2.7 38.2 ± 4.3 39.9 ± 2.1 38.9 ± 1.5
PT (s) 13.1 ± 0.4 13.0 ± 0.4 11.8 ± 0.3 12.4 ± 0.1
M3BIM (24 mg/kg), solvent control (0.5 % DMSO), or a phosphate-buffered
saline (PBS) was injected (i.p.) in mice for 30 or 60 min. The platelet-poor
plasma was obtained for assay the activated partial thromboplastin time (APTT)
and prothrombin time (PT). Data are presented as the means ± SEM (n = 8)
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